Your trusted guide to clinical trials
Find clinical trials relevant to you, near you. Powered by AI.
Browse Trials by Condition
- Neoplasms 18,336
- Lymphocytic Leukemia, Acute 15,317
- Muscular Dystrophy 15,154
- Metastatic Cancer 10,936
- Neoplasm Metastasis 10,819
- Menstruation 8,794
- Surgery 8,770
- Carcinoma 6,658
- Uterine Fibroids 6,571
- Neurologic Disorders 6,499
- Pain 5,897
- Chemotherapy 5,309
- Wounds 4,979
- Lung Disease 4,726
- Allergy 4,144
- Vascular Diseases 3,926
- Vision Loss 3,750
- Heart Disease 3,222
- Cardiac Disease 3,207
- Depression 3,050
- Inflammation 2,894
TrialX — your clinical trial finder
A new, easy way to participate in clinical studies.
You are in great company.
Institutes that trust us.
New & updated studies
Browse all studies
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose …
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of Lu-177-DGUL on the anti-tumor activity that aims to simultaneously evaluate diagnostic and therapeutic validity.
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of …
MitoQ for Fatigue in Multiple Sclerosis (MS)
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
Your clinical trial journey
Find a study
Search or browse for a clinical trial near you.
Check Eligibility
Learn more about the trial and check to see if you are eligible to take part in it.
Participate
If you prequalify, connect with the study team and let your trial journey begin!
Accelerating clinical research powered by AI
Building patient connection for a better future
Join us in our mission to help accelerate clinical research.
We are on a mission to make 1 billion actions made towards clinical research. ‘Actions’ are anything from searching for trials, sharing a trial, getting in touch with a study team — or something as simple as becoming a volunteer.